Adjuvant systemic therapy of early stage breast cancer

Current Treatment Options in Oncology

Volumn 4, Issue 2, 2003, Pages 141-150

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant Tamoxifen; Anastrozole; Early Stage Breast Cancer; Paclitaxel; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; DOCETAXEL; DRUG DERIVATIVE; ENZYME INHIBITOR; PACLITAXEL; TAXOID;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; PATHOLOGY; REVIEW;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASM STAGING; PACLITAXEL; TAXOIDS;

EID: 0037928430     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0015-x     Document Type: Article

References (17)

1. Fokotomi T, Akashi-Tanaka S: Prognostic and predictive factors in the adjuvant treatment of breast cancer. Breast Cancer 2002, 9:95–99. A thorough discussion of prognostic and predictive factors for early stage breast cancer is provided. Factors which have not been validated prospectively are highlighted. DOI: 10.1007/BF02967572
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 352:930–942. The report represents a detailed analysis of the last published meta-analysis of randomized adjuvant chemotherapy trials for early stage breast cancer. The impact of treatment duration, anthracyclines, hormone receptor status, and the addition of tamoxifen to chemotherapy are detailed.
3. Henderson IC, Berry D, Demetri G, et al.: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:101a.
4. The National Institutes of Health Consensus Development Conference: adjuvant therapy for breast cancer. Bethesda, Maryland, USA. J Natl Cancer Inst Monogr 2001, 30:1–152. The monograph reflects the content of lectures delivered by participants in the National Institutes of Health Consensus Development Conference. The monograph serves as a primer on all aspects of adjuvant therapy of breast cancer. In addition, perspective is given to areas where there are gaps in knowledge or data.
5. Thomas E, Buzdar A, Theriault R, et al.: Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial [abstract]. Proc Am Soc Clin Oncol 2000, 19:74a.
6. Buzdar AU, Singletary SE, Valero V, et al.: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8:1073–1079.
7. Nabholtz JM, Pienkowski T, Mackey J, et al.: Phase III trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study [abstract]. Proc Am Soc Clin Oncol 2002, 21:36a.
8. Citron M, Berry D, Cirrincione C, et al.: Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741) [abstract]. Breast Cancer Res Treat 2002, 76:S32.
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351:1451–1467. The report is a detailed analysis of randomized adjuvant tamoxifen trials. The large number of patients in these trials and the mature follow-up confirms the efficacy of tamoxifen.
10. Fisher B, Digmar J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684–690. An update of the National Adjuvant Breast and Bowel Project B-14 trial continues to reaffirm that 5 years of adjuvant tamoxifen is optimal. Other trials that have addressed the optimal duration of tamoxifen are discussed. DOI: 10.1093/jnci/93.9.684
11. Stewart HJ, Forrest AP, Everington D, et al.: Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group Br J Cancer 1996, 74:297–299.
12. Albain KS, Green SJ, Ravdin PM, et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG 8814) [abstract]. Proc Am Soc Clin Oncol 2002, 21:37a.
13. Pico C, Martin M, Jara C, et al.: Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrently (Con) versus sequential (Sec): randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients. GEICAM 9401 study [abstract]. Proc Am Soc Clin Oncol 2002, 21:37a.
14. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131–2139. This is the first report of the ATAC (Arimidex, tamoxifen, alone, or in combination) trial, which shows an apparent advantage for anastrozole over tamoxifen. The report dissects the data related to clinical efficacy and tolerability. A trial reported by Buzdar et al. [15] confirms the lasting superiority of anastrozole over tamoxifen with longer follow-up.
15. Buzdar A, ATAC Trialists’ Group: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer: updated efficacy results based on a median follow-up of 47 months [abstract]. Breast Cancer Res Treat 2002, 76:13. DOI: 10.1023/A:1020305615033
16. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792. DOI: 10.1056/NEJM200103153441101
17. Slamon D, Pegram M: Rationale for trastuzamab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001, 28:13–19. The review places data into context from clinical trials using trastuzamab in patients with HER2-positive metastatic breast cancer. A discussion of the design and rationale for ongoing clinical trials involving trastuzamab is provided. DOI: 10.1016/S0093-7754(01)90188-5